- Home
- OM vs SGMT Comparison
OM vs SGMT Comparison
Compare OM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- SGMT
- Stock Information
- Founded
- OM 2003
- SGMT 2006
- Country
- OM United States
- SGMT United States
- Employees
- OM N/A
- SGMT N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SGMT
- Sector
- OM Health Care
- SGMT
- Exchange
- OM Nasdaq
- SGMT Nasdaq
- Market Cap
- OM 305.5M
- SGMT 269.2M
- IPO Year
- OM 2020
- SGMT 2023
- Fundamental
- Price
- OM $18.53
- SGMT $10.24
- Analyst Decision
- OM Buy
- SGMT Strong Buy
- Analyst Count
- OM 2
- SGMT 6
- Target Price
- OM $33.00
- SGMT $26.83
- AVG Volume (30 Days)
- OM 411.2K
- SGMT 863.2K
- Earning Date
- OM 08-06-2025
- SGMT 08-13-2025
- Dividend Yield
- OM N/A
- SGMT N/A
- EPS Growth
- OM N/A
- SGMT N/A
- EPS
- OM N/A
- SGMT N/A
- Revenue
- OM $115,273,000.00
- SGMT N/A
- Revenue This Year
- OM $10.80
- SGMT N/A
- Revenue Next Year
- OM $11.99
- SGMT N/A
- P/E Ratio
- OM N/A
- SGMT N/A
- Revenue Growth
- OM N/A
- SGMT N/A
- 52 Week Low
- OM $5.85
- SGMT $1.73
- 52 Week High
- OM $59.33
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- OM 48.27
- SGMT 66.92
- Support Level
- OM $17.16
- SGMT $8.79
- Resistance Level
- OM $19.60
- SGMT $9.83
- Average True Range (ATR)
- OM 1.17
- SGMT 0.80
- MACD
- OM -0.16
- SGMT -0.07
- Stochastic Oscillator
- OM 35.06
- SGMT 59.93
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.